By
Trending Posts
Is Exscientia Setting the Financial Benchmark for AI…
Strategic Insights Exscientia has emerged as one of the most financially validated AI-drug discovery companies, translating computational precision…
Is Insilico Medicine Redefining Drug Discovery as AI…
Executive Summary Insilico Medicine has emerged as one of the most influential AI-native biotechnology companies, reshaping how the…
Can Vanda Pharma’s FDA Approval of Nereus Unlock…
New York | Jan, 2026 — Vanda Pharmaceuticals Inc. achieved a major regulatory and commercial milestone after the…
Can Bristol Myers Squibb’s $330 Million AI Investment…
Global – December 31, 2025 — Bristol Myers Squibb (BMS) significantly expanded its commitment to artificial intelligence (AI)…
Can GSK’s $340 Million AI Investment in 2025…
Global – December 31, 2025 — GlaxoSmithKline plc (GSK) significantly expanded its use of artificial intelligence (AI) throughout…
Can AstraZeneca’s $390 Million AI Investment in 2025…
Global – December 31, 2025 — AstraZeneca plc significantly expanded its commitment to artificial intelligence (AI) throughout 2025,…
Can Merck’s $300 Million AI Investment in 2025…
Global – December 31, 2025 — Merck & Co., Inc. significantly expanded its commitment to artificial intelligence (AI)…
Can Gilead’s $260 Million AI Investment in 2025…
Global – December 31, 2025 — Gilead Sciences, Inc. expanded its commitment to artificial intelligence (AI) throughout 2025…
Can Sanofi’s $380 Million AI Investment in 2025…
Global – December 31, 2025 — Sanofi S.A. made significant investments in artificial intelligence (AI) across discovery, clinical…
Trending Posts
Latest Stories
Can Takeda’s $1.7 Billion Iambic Deal Redefine AI-Driven Small-Molecule Drug Discovery?
Executive Summary In a landmark AI-biopharma transaction, Takeda Pharmaceutical Co Ltd has entered a multi-year…
Pfizer Repositions for Sustainable Growth in 2025 as Core Therapeutic Franchises Reassert Leadership
Pfizer Inc. reported full-year 2025 revenues of $62.6 billion, marking a pivotal year in the…
Eli Lilly Delivers Transformational Growth in 2025, Anchored by Metabolic Leadership and Innovation Execution
Indianapolis, IN – February 2026 – Eli Lilly and Company reported exceptional full-year financial and…
Merck Reinforces Oncology Leadership and Therapeutic Area Depth with Robust 2025 Performance
Rahway, NJ – February 2026 – Merck & Co., Inc. reported strong full-year 2025 financial…
Gallery
